Insider buying last 90 days
No open-market insider purchases were filed for MEDP in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every MEDP insider filing, plotted on the chart in Gekko.Open MEDP in Gekko
NASDAQ: MEDP
Medpace (MEDP) Stock Analysis & Forecast
Sep 28 close
$615.94−2.94 (−0.5%)
Gekko Brief
AI summaryThis week's attention on Medpace centers on a series of insider sales by CEO August J. Troendle, including transactions totaling approximately $6.75 million, $44.4 million, and $27.4 million across multiple dates in late September, following the company's Q2 2026 results that had surpassed expectations. A comparison piece also weighed Medpace against Concentra Group (CON) on relative value grounds. These sales come after shares had climbed 37% over six months, with market capitalization reaching $17.27 billion, alongside continued share buybacks and positive analyst revisions referenced in coverage of the CEO transactions.
Medpace closed at $615.94, down 0.5%, sitting above both its 50-day average of $595.14 and 200-day average of $522.81, with the shorter average above the longer one. The GekkoIndex reads 53.2, placing the stock in the Neutral zone, up 4.7 over the past five readings. Price sits 21.7% above Gekko Fair Value of $505.91.
The next earnings date falls on 21 October 2026, 22 days away, landing inside a typical 20-trading-day holding window. The prior quarter saw EPS of $4.25 versus a $3.98 estimate, with a 13.9% reaction, and the company has beaten estimates in 8 of its last 8 quarters, with an average absolute reaction of 17.3%. Seasonality from this point in the calendar has averaged a 14.6% move over the next 20 trading days across 5 years, rising in 4 of them. No insider, Congress, or unusual options activity appears in the current windows tracked.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Medpace price vs fair value
Close $615.94200-day averageGekko Fair Value $505.91
Medpace quick facts
- Market cap
- $17.19B
- P/E ratio
- 36.2
- Forward P/E
- 32
- EPS, TTM
- $17.13
- Revenue, TTM
- $2.78B
- Profit margin
- 17.7%
- Dividend yield
- —
- Beta
- 1.15
- Volume
- 238,731 avg 233,507
- 1-year return
- +26.2%
- Typical daily move
- ±2.4%
- Typical 20-day move
- ±6.8%
- 50-day average
- $595.14
- 200-day average
- $522.81
- Next earnings
- Oct 21
- Shares outstanding
- 27.91M
Medpace swing-trade checklist
Medpace scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $615.94 is above the 50-day ($595.14) and 200-day ($522.81) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
53.2, Neutral
Reading 53.2 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
21.7% above
Price is 21.7% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 22 days
Reports on Oct 21, 2026, 22 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+14.6% on average
From this point in the calendar, the next 20 trading days averaged +14.6% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Medpace stock chart and price history
Medpace closed at $615.94 on Sep 28, 2026, +26.2% over the past year, inside a 52-week range of $373.00 to $677.90.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +0.7%
- 3 months
- +15.2%
- 6 months
- +36.5%
- 1 year
- +26.2%
The full MEDP chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open MEDP in Gekko
Follow Medpace through every session
Put MEDP on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track MEDP in GekkoFree for 7 days. No credit card required.
About Medpace
Medpace provides contract research services that support the clinical development of new medical products. It works with pharmaceutical, biotechnology, and medical device companies, guiding studies from early Phase I testing through to post-market Phase IV surveillance. The company is recognized for covering this full span of drug and device development under one roof.
Its work spans designing trial programs, running central laboratory operations, managing projects and regulatory filings, overseeing clinical trials, and handling data management and pharmacovigilance. Medpace also assists clients with new drug application submissions and continued clinical monitoring after products reach the market. Beyond these core services, it operates bio-analytical laboratories, conducts human pharmacology studies, and offers imaging and ECG reading services used in clinical research. Its client base extends across North America, Europe, and Asia.
Medpace was founded in Cincinnati, Ohio, in 1992, where it remains based. Its shares are listed on the NASDAQ under the ticker MEDP.
- Listed
- NASDAQ
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Website
- medpace.com
Medpace GekkoIndex: the smart money zone
Medpace’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.2, in the Neutral zone, up 4.7 points over five sessions.
53.2Neutral
Up 4.7 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 28 | −0.1% | +1.0% | ||
| Accumulation | 176 | +1.8% | +2.3% | ||
| Neutral (current zone) | 412 | +0.5% | +2.5% | ||
| Distribution | 49 | −0.6% | +8.3% | ||
| Selling | 7 | Too few readings yet | |||
Average MEDP share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the MEDP price, zone by zone.Track MEDP in Gekko
Is Medpace stock overvalued? Gekko Fair Value
Medpace trades 21.7% above Gekko Fair Value of $505.91, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Medpace shares are worth, recalculated every trading day.
$505.91
Gekko Fair Value, Sep 26, 2026
21.7% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open MEDP in Gekko
Medpace insider and Congress trading
No open-market insider purchases were filed for Medpace, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in MEDP were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for MEDP, plotted on the chart in Gekko.Open MEDP in Gekko
Buybacks
Medpace has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $294.8M
- As a share of market cap
- 1.71%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds MEDP.
0added0opened1trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Medpace earnings: next date and track record
Medpace reports on Oct 21, 2026 (22 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Oct 21, 2026
22 days away
- EPS estimate
- $4.41
- Revenue estimate
- $714.3M
8 of 8reports beat the EPS estimate
±17.3%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 22, 2026 AI summary
- What they said
- Medpace reported Q2 2026 revenue of $707.3M, up 17.2% YoY, with EBITDA of $153.4M (+17.6%) and net income of $121.4M (+34.5%). EPS was $4.25 vs $3.10 prior year. Net new business awards surged 28.2% to $795.7M (1.13x book-to-bill), with backlog reaching ~$3B. The company repurchased ~706K shares for $294.7M and generated $162M in operating cash flow.
- Guidance
- Full year 2026 revenue guidance raised to $2.805B-$2.885B (10.9%-14% growth). EBITDA expected at $618M-$642M and EPS of $17.25-$17.95. No additional share repurchases assumed in guidance.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 22, 2026 | $4.25 est $3.98 | $707.3M est $689.5M | +13.9% |
| Apr 22, 2026 | $4.28 est $3.96 | $706.6M est $697.6M | −23.6% |
| Feb 9, 2026 | $4.67 est $4.19 | $708.5M est $689.3M | −17.7% |
| Oct 22, 2025 | $3.86 est $3.53 | $659.9M est $641.0M | +9.3% |
| Jul 21, 2025 | $3.10 est $2.98 | $603.3M est $538.8M | +53.2% |
| Apr 21, 2025 | $3.67 est $3.06 | $558.6M est $526.3M | −4.7% |
| Feb 10, 2025 | $3.68 est $3.12 | $536.6M est $539.7M | −7.4% |
| Oct 21, 2024 | $3.01 est $2.78 | $533.3M est $534.9M | −8.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Medpace stock forecast and analyst price targets
Analysts’ average 12-month price target for Medpace is $581.83, −5.5% from the last close, from 11 firms rating the stock in the last 90 days.
$581.83consensus 12-month target, −5.5% from the last close
Now $615.94Avg $581.83
Low $450High $692
Each firm’s latest rating in the last 90 days: 11 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 17 | Truist Financial | — | — |
| Sep 14 | Jefferies | $560 | −9.1% |
| Jul 28 | Truist Financial | $609 | −1.1% |
| Jul 27 | BMO Capital | $600 | −2.6% |
| Jul 24 | Mizuho Securities | $665 | +8.0% |
+2.5%average 20-day move after past Neutral readings
+14.6%average move over the next 20 trading days in the last 5 years
±2.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Medpace seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Medpace averaged +14.6% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +4.3% | 5 of 5 |
| Next 10 trading days | +1.5% | 3 of 5 |
| Next 15 trading days | +2.3% | 4 of 5 |
| Next 20 trading days | +14.6% | 4 of 5 |
| Next 30 trading days | +19.7% | 5 of 5 |
For scale, MEDP’s typical 20-trading-day move in either direction is about 6.8%.
Medpace market cap and key statistics
Medpace’s market cap is $17.19B, with a P/E ratio of 36.2 and revenue of $2.78B over the last twelve months.
Valuation
- Market cap
- $17.19B
- P/E ratio
- 36.2
- Forward P/E
- 32
- EPS, TTM
- $17.13
- Gekko Fair Value
- $505.91
Trading
- Volume
- 238,731
- Avg volume, 20 days
- 233,507
- 52-week high
- $677.90
- 52-week low
- $373.00
- Shares outstanding
- 27.91M
Financials
- Revenue, TTM
- $2.78B
- Profit margin
- 17.7%
- Return on equity
- 162.1%
- Quarterly earnings growth, YoY
- +37.1%
Risk and income
- Beta
- 1.15
- Typical daily move
- ±2.4%
- Typical 20-day move
- ±6.8%
Medpace stock news this week
Coverage of Medpace this week reads negative: 0 positive, 6 neutral and 10 negative headlines.
- CON or MEDP: Which Is the Better Value Stock Right Now?Zacks Investment Research, Sep 28
- Envestnet Asset Management Inc. Cuts Position in Medpace Holdings, Inc. $MEDPDefense World, Sep 28
- Medpace Holdings CEO August J. Troendle sells $6.75m in stock By Investing.comInvesting.com South Africa, Sep 27
- Medpace Holdings CEO August J. Troendle sells $6.75m in stockInvesting.com, Sep 27
- Medpace Holdings CEO August Troendle sells $44.4m stockInvesting.com, Sep 27
- Form 4 Medpace Holdings Inc For: 27 September By Investing.comInvesting.com India, Sep 27
Medpace peers
Medpace’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| SHOPShopify | Neutral | 5.0% above |
| CTASCintas | Neutral | 11.5% above |
| PYPLPayPal | Accumulation | 4.6% below |
| XYZBlock | Accumulation | 2.5% above |
| CPAYCorpay | Accumulation | 18.1% below |
| FISVFiserv | Buying | 40.6% below |
A peer links to its own page where one exists.
Medpace stock FAQ
What is Medpace’s market cap?
Medpace’s market cap is $17.19B at the Sep 28, 2026 close of $615.94, with 27.91M shares outstanding. The shares trade on a P/E ratio of 36.2.
What is the Medpace stock forecast?
The consensus analyst 12-month price target for Medpace is $581.83, −5.5% from the last close. Of the 11 firms that rated the stock in the last 90 days, 2 rate it a buy, 9 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Medpace stock overvalued or undervalued?
On Gekko’s estimate Medpace is overvalued: the Sep 28, 2026 close of $615.94 is 21.7% above Gekko Fair Value of $505.91. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Medpace report earnings next?
Medpace is expected to report on Oct 21, 2026 (22 days away). Analysts expect earnings of $4.41 per share on revenue of $714.3M. Medpace beat the earnings estimate in 8 of its last 8 reports, moving 17.3% on average across the report.
What is Medpace’s 52-week high and low?
Medpace’s 52-week high is $677.90 and its 52-week low is $373.00; it closed at $615.94 on Sep 28, 2026, +26.2% over the past year.
Is Medpace stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and seasonality), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Medpace the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.